AdisInsight informing drug development in asthma

Worldwide, it is estimated that approximately 334 million people currently suffer from asthma, and 250,000 deaths are attributed to the disease each year. The prevalence of the disease is continuing to grow, and the overall prevalence is estimated to increase by 100 million by 2025. Asthma is a chronic condition with no known cure, but management options are available to improve quality of life and allow patients to live an uninhibited life. 

The landscape of asthma has changed considerably after 40 years of inhaled corticosteroid development and nearly 20 years since the first monoclonal antibodies were approved. New members of pharmacological families and more effective drug-delivery devices have been designed but the proportion of uncontrolled patients, unfortunately, remains stable. The most promising treatments now rely on targeted therapies that encourage the improvement of the characterization of patients. 

How AdisInsight can help

AdisInsight can help you keep up with the rapid pace of development in immunological and respiratory disorders. It is an integrated database of profiles authored by Springer Nature editors sourced from publicly available information from journals, conferences, trial registries, media releases, company websites, and government filings about pharmaceutical development programs, clinical trial studies, and published individual case safety reports. Information in AdisInsight is updated daily to keep you informed of the latest information impacting your research. Start searching on AdisInsight

Global Drug Pipeline

According to AdisInsight, the global drug pipeline for Asthma currently contains 1,288 unique drug programs that are either marketed, in regulatory approval, in clinical development, in preclinical development, or have been discontinued for the treatment of asthma. 

New Content Item

Read further

An analysis of the global pipeline reveals high level of research activity in the treatment of allergic asthma.  23 drug development programs are in late stage clinical development. Aquinox Pharmaceuticals is in phase II development with Rosiptor, a first-in-class SH2-containing inositol phosphate 5-phosphatase (SHIP1) activator for the treatment of inflammation and inflammatory pain.  Aquinox Pharmaceuticals has completed two randomized, double-blind, placebo-controlled phase IIa trials in the UK.  The first proof-of-concept trial evaluated Rosiptor in patients with mild-to-moderate allergic asthma exposed to an asthma-inducing allergen. The second trial assessed two different doses of Rosiptor in volunteers exposed to an environmental inflammatory stimulus. Both trials produced promising result meeting the primary endpoint to reduce inflammatory cells and markers in sputum.

View the full drug profile 

Global Clinical Trial Landscape

New Content Item (1)AdisInsight shows 10,115 clinical studies investigating pharmaceutical treatment for asthma being conducted in 104 countries. Some of these studies will be active in either the planning, recruitment, or administration stage while other will be inactive either completed or discontinued. The clinical trial map shown below aggregates information across all trials researching asthma to show where active clinical studies are taking place at a regional level.

Read further

One of those clinical studies taking place in the USA is phase II trial studying pretreatment with albuterol vs. montelukast in exercise induced bronchospasm in children. This Sanofi affiliated trial is active and no longer recruiting subjects. Results from this study were published in the Journal Pharmacotherapy. The trial met the primary outcome, the maximal change in FEV1 (forced volume of expiration in 1 second) after exercise. The study demonstrated that salbutamol was more effective than montelukast, for the prevention of exercise-induced bronchospasm, in children and adolescents with asthma. After exercise, the maximal change in forced expiratory volume in 1 second was significantly reduced following treatment with salbutamol compared with montelukast (0.7% vs 18.3%; p<0.01).  

View the full profile

Organizations Active in Asthma

According to AdisInsight there are 994 organizations involved in researching drug development programs for the treatment of asthma.  420 of these organizations have drugs in active development for asthma.  The table below shows the top 15 organizations ranked according by the number of drug programs in development for asthma.  

Many of these organizations use AdisInsight to inform their strategic decisions as they work to advance drug therapies for the treatment of asthma.  Whether they are identifying unmet clinical needs, monitoring the therapy area landscape, researching innovative disease targets, or planning clinical trial programs, AdisInsight is making drug development more efficient. 

New Content Item

Biomarkers for Asthma

Biomarker selection is becoming an essential part of clinical development. Successful use of biomarkers can accelerate the pace of development by predicting drug efficacy more quickly, identifying optima patient populations, and early detection of safety signals. 

AdisInsight catalogs 344 biomarkers associated with the drugs being studied to treat asthma.  108 of biomarkers are being used as outcome measures, 52 are being used to detect safety issues, 62 are being used for patient inclusion, and 18 are being used for patient exclusion. The top 15 biomarkers being used in asthma drug research are shown below.

New Content Item